This single arm study will evaluate the efficacy and safety of sequential treatment with Diavobet (betamethasone propionate 0.5mg/g plus calcipotriol hydrate 50 micrograms/g) once daily for 4 weeks followed by Daivonex (calcipotriol hydrate 50 micrograms/g) twice daily for 4 weeks, in the control of signs and symptoms in patients with mild to moderate psoriasis. Only patients showing a \>50% response to Daivobet will progress to the Daivonex maintenance phase. The anticipated time on study treatment is \<3 months, and the target sample size is 100-500 individuals.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
200
50 micrograms/g bid for 4 weeks (weeks 5-8) in patients who have shown a \>50% response to Daivobet from weeks 0-4.
Unnamed facility
Belém, Brazil
Unnamed facility
Belo Horizonte, Brazil
Unnamed facility
Botucatu, Brazil
Unnamed facility
Brasília, Brazil
Unnamed facility
Campinas, Brazil
Unnamed facility
Curitiba, Brazil
Unnamed facility
Rio de Janeiro, Brazil
Unnamed facility
Rio de Janeiro, Brazil
Unnamed facility
Salvador, Brazil
Unnamed facility
São Paulo, Brazil
PASI reduction
Time frame: Weeks 4 and 8
AEs.
Time frame: Throughout study
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.